Bromifar indications
Bromifar hydrochloride SYRUP indicated for cough associated with wheeziness (bronchospasm) and tenacious phlegm (sputum).
Uses of Bromifar in details
Bromifar is used to treat breathing difficulties caused by excessive mucus secretions in the air passages associated with respiratory tract infections.
Bromifar description
Each tablet also contains lactose, maize or potato starch, gelatine and magnesium stearate as excipients.
The oral/inhalation solution also contains tartaric acid and methyl parahydroxybenzoate as excipients.
The syrup also contains tartaric acid, benzoic acid, sodium carboxymethylcellulose, glycerol, sorbitol solution, pharma flavor and ethanol as excipients.
Each capsule also contains lactose, cornstarch and magnesium stearate as excipients.
Bromifar HCl is N-cyclohexyl-N-methyl-(2-amino-3,5-dibromobenzyl)amine hydrochloride.
Bromifar dosage
Unless otherwise prescribed, the following doses are recommended:
Tablet: Adults and Children >12 years: 8 mg (1 tab) thrice daily; 6-12 years: 4 mg (½ tab) thrice daily; 2-6 years: 4 mg (½ tab) twice daily.
Oral Solution:
Adults and Children >12 years: 4 mL thrice daily; 6-12 years: 2 mL thrice daily; 2-6 years: 20 drops thrice daily; <2 years: 10 drops thrice daily.Inhalation Solution (with aerosol apparatus): It is generally recommended to warm inhalation solution to body temperature before inhalation. Patients with bronchial asthma may be advised to commencing inhalation after they have taken their regular bronchospasmolytic therapy.
Adults: 4 mL. Children >12 years: 2 mL; 6-12 years: 1 mL; 2-6 years: 10 drops; <2 years: 5 drops. All doses to be taken twice daily.
The solution may be diluted 1:1 in physiological saline solution. In order to avoid precipitation, the solution should be inhaled immediately after mixing. The combined administration of inhalation and oral application intensifies the effect, and is especially suited for the commencement of treatment in cases where the full effect is to be reached quickly.
Syrup: Adults and Children >12 years: 5 ml (1 tsp) thrice daily.
At commencement of treatment, it may be necessary to increase the total daily dose up to 48 mg in adults.
The syrup is sugar-free and therefore suitable for diabetics and small children.
Ampoule: Severe cases, before and after surgical intervention: 1 amp SC, IM or IV (duration of injection: 2-3 min) 2-3 times daily.
Capsule: Adults: 1 cap 3 times daily.
It is recommended for the initial phase of treatment usually lasting not more than a week.
Patients being treated with Bromifar should be notified of an expected increase in the flow of secretions.
Bromifar interactions
A reduction in dose of cardiac glycosides (e.g. digitalis) and quinidine might become necessary in patients suffering from congestive cardiac failure because of the positive inotropic effect of orciprenaline sulphate.
Bromifar hydrochloride SYRUP should not be administered concomitantly with beta-blocking agents, due to orciprenaline’s reversal of anti-hypertensive action.
The concomitant use of other sympathomimetic agents should be carefully controlled to avoid potentiation of effects.
Bromifar side effects
Bromifar’s pharmacological action may lead to gastric irritation. A transient rise in serum aminotransferase values have been reported due to Bromifar.
Orciprenaline sulphate, as a sympathomimetic agent, may precipitate a wide range of adverse effects. Side-effects include fear; anxiety, restlessness, tremor, insomnia, confusion, irritability, weakness and psychotic states. Appetite may be reduced and nausea and vomiting may occur. A rise in blood pressure which may produce cerebral haemorrhage and pulmonary oedema, tachycardia and cardiac arrhythmias, anginal pain, palpitations, and cardiac arrest. Hypotension with dizziness and fainting and flushing may occur. Other effects that may occur include difficulty in micturition and urinary retention; dyspnoea; weakness; headache; disturbances of glucose metabolism; sweating and hypersalivation. Muscle cramps or twitching or unpleasant taste may occur.
Bromifar contraindications
Bromifar hydrochloride SYRUP is contra-indicated in patients with known hypersensitivity to sympathomimetic amines or any of the other ingredients; hypertrophic obstructive cardiomyopathy; and tachyarrhythmia.
Sympathomimetics, such as orciprenaline sulphate, may interact with monoamine oxidase inhibitors (MAOI), and therefore Bromifar hydrochloride SYRUP should not be given to patients receiving such treatment or within 14 days of MAOI treatment termination.
Safety in pregnancy and lactation has not been established.
Active ingredient matches for Bromifar:
Bromhexine in Indonesia.
List of Bromifar substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Bromicof (Mexico) | |
| Bromika (Indonesia) | |
| Bromilar (Uruguay) | |
| Bromilco (Guatemala) | |
| Bromiramin (Greece) | |
| Bromisal | |
| Bromisal 200+16+4 Tablet (Indamed Pharmaceuticals Pvt. Ltd) | $ 0.01 |
| Bromisol (Tunisia) | |
| Bromitol | |
| Bromitol 200+8+2 Tablet (Antiseptic Pharmaceuticals) | $ 0.02 |
| Brommy (Thailand) | |
| Brommy syr 4 mg/5 mL 60 mL x 1's (B L Hua) | |
| Bromocal (Portugal) | |
| Bromocix (Taiwan) | |
| Bromocix 8 mg | |
| Bromocof (India) | |
| Bromocof Bromhexine hydrochloride 4 mg, Phenylephrine 2.5 mg, Menthol0.75 mg. SYR / 60ml (Infalife (Invision Medi Sciences)) | $ 0.43 |
| 60ml (Infalife (Invision Medi Sciences)) | $ 0.43 |
| Bromocof 60 ml Syrup (Infalife (Invision Medi Sciences)) | $ 0.04 |
| BROMOCOF syr 60ml (Infalife (Invision Medi Sciences)) | $ 0.43 |
| Bromolin DT | |
| Bromolin DT 125+4 Tablet (Protec (Cipla Ltd)) | $ 0.03 |
| Bromolin DT 250+4 Tablet (Protec (Cipla Ltd)) | $ 0.05 |
| Bromolin Rediuse | |
| Bromolin Rediuse 30 ml Syrup (Protec (Cipla Ltd)) | $ 0.04 |
| Bromolin Rediuse Liquid (Protec (Cipla Ltd)) | $ 0.31 |
| Bromolin Rediuse Suspension (Protec (Cipla Ltd)) | $ 0.92 |
| Bromolit (Bangladesh) | |
| Bromolite | |
| Bromolite 100 ml Syrup (Elite Pharma Pvt Ltd) | $ 0.04 |
| Bromosal | |
| Bromosal 100 ml Syrup (Smilax Pharmaceuticals) | $ 0.01 |
| Bromoson (Hong Kong, Myanmar, Thailand) | |
| Bromoson 8 mg x 1, 000's (Unison) | |
| Bromoson 4 mg/5 mL x 60 mL (Unison) | |
| Bromotex (Bangladesh) | |
| Bromox (Venezuela) | |
| BROMOX Liquid / 125mg per 5ml / 60ml units (Mamta Pharmaceuticals) | $ 0.28 |
| BROMOX Liquid / 125mg per 5ml / 30ml units (Mamta Pharmaceuticals) | $ 0.21 |
| BROMOX Capsule/ Tablet / 250mg - 8mg / 10 units (Mamta Pharmaceuticals) | $ 0.42 |
| BROMOX Capsule/ Tablet / 125mg / 10 units (Mamta Pharmaceuticals) | $ 0.23 |
| BROMOX Capsule/ Tablet / 500mg / 10 units (Mamta Pharmaceuticals) | $ 0.72 |
| Bromox 250+8 Capsule (Mamta Pharmaceuticals) | $ 0.04 |
| Bromox 8 mg Tablet (Mamta Pharmaceuticals) | $ 0.01 |
| Bromox 500 mg Capsule (Mamta Pharmaceuticals) | $ 0.07 |
| Bromox 250 mg Capsule (Mamta Pharmaceuticals) | $ 0.04 |
| Bromox 60 ml Syrup (Mamta Pharmaceuticals) | $ 0.04 |
| BROMOX 125MG TABLET 1 strip / 10 tablets each (Mamta Pharmaceuticals) | $ 0.15 |
| BROMOX 250MG CAPSULE 1 strip / 10 capsules each (Mamta Pharmaceuticals) | $ 0.43 |
| BROMOX 500MG CAPSULE 1 strip / 10 capsules each (Mamta Pharmaceuticals) | $ 0.72 |
| Bromox 125mg Tablet (Mamta Pharmaceuticals) | $ 0.02 |
| Bromox 250mg Capsule (Mamta Pharmaceuticals) | $ 0.04 |
| Bromox 500mg Capsule (Mamta Pharmaceuticals) | $ 0.07 |
See 1877 substitutes for Bromifar | |
References
- PubChem. "bromhexine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Bromhexine". http://www.drugbank.ca/drugs/DB09019 (accessed September 17, 2018).
- MeSH. "Expectorants". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Bromifar are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Bromifar. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
